Curious about VOXZOGO? Not sure how to get started with VOXZOGO? This webinar features parent, Erin Parsons, who is here to help you get answers to questions about VOXZOGO and share their experience. Still have questions? Join our live Q&A where you and your child can ask our panel questions.
This event is intended for families with a child aged 5 years and older with achondroplasia. Kids are welcome to attend!
VOXZOGO is an FDA-approved therapy for increasing linear growth in children with achondroplasia aged 5 years and up whose growth plates are still open.
VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should be well fed and hydrated in the hour before receiving VOXZOGO.
Clinical Professor of Pediatrics
University of Wisconsin School of Medicine and Public Health
Madison, WI
Parent of a child taking VOXZOGO
*Required fields.
This event is intended for families with a child aged 5 or older with achondroplasia.
What is the most important safety information about VOXZOGO?
What are the most common side effects of VOXZOGO?
How is VOXZOGO taken?
What should you tell the doctor before or during taking VOXZOGO?
You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see additional safety information in the full Prescribing Information and Patient Information.
What is VOXZOGO used for?
What is VOXZOGO used for?
What is the most important safety information about VOXZOGO?
What are the most common side effects of VOXZOGO?
How is VOXZOGO taken?
What should you tell the doctor before or during taking VOXZOGO?
You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see additional safety information in the full Prescribing Information and Patient Information.